New Data for Nebivolol after In Silico PK Study: Focus on Young Patients and Dosage Regimen.

Pharmaceutics · 2022 · PMC9502491 · PMID 36145659

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

slightly significantno p-value reported

Moreover, according to Cohen-Solal et al., a distinction between patients with moderate renal impairment and patients with normal or mild renal impairment demonstrated a comparable safety profile (except from a slightly significant increase in bradycardia) [ 20 ].

also in 1,756 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.